Lilly's E-Venture Fund: Getting In At The Bottom
This article was originally published in Start Up
Executive Summary
With investors still generally staying out of e-health, a couple of Big Pharma companies think it's time to get in. First, Merck & Co. Inc. announced last November that former Merck-Medco chairman, Per Lofberg would head a $100 million fund dedicated to Internet Health care. And now, Eli Lilly & Co. has just launched the $50 million e.Lilly Venture Fund. Lilly's fund, which will focus on companies with technologies that the company can use, rather than return on investment, will make investments of up to $3 million in 12 to 15 companies over the next year or so.
You may also be interested in...
Corporate Venture Capital's Complex Agenda
Several forces--rapid technological obsolescence, the impact of information technology on health care, merger integrations, and the need for double digit revenue growth--have caused increasing numbers of large pharmaceutical and medical device companies to create new corporate venture capital groups. But compared to traditional VC firms, whose only goal is to make money for limited partners, corporate VCs have a heavy agenda. They must choose portfolio companies while balancing often-competing goals of strategic benefit and financial return.
AureoGen Biosciences Inc.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain Therapeutics
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.